iOnctura B.V.’s €80 Million Series B Financing Round

Osborne Clarke has advised iOnctura B.V. on the deal,iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has completed a €80 million Series B…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Marco Zingaro

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here